ArticleDiscover oncology2026
Construction of a SEMA3 family-based model to predict prognosis and molecular subtypes in pancreatic ductal adenocarcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) remains a highly aggressive malignancy with a complex tumor microenvironment. Although the class-3 semaphorin (SEMA3) gene family has been implicated in tumor progression and immune regulation, its specific role and clinical relevance in PDAC are not yet fully understood.
methodsMulti-omics data from public cohorts (TCGA and GEO) were integrated to perform unsupervised clustering based on SEMA3 family expression. A prognostic risk model was constructed using univariate Cox and LASSO regression, and validated in an independent cohort. Immune infiltration, mutation profiling, and drug sensitivity analyses were conducted. Single-cell and spatial transcriptomic data were used to characterize the expression and spatial distribution of SEMA3 genes at cellular resolution.
resultsTwo molecular subtypes with distinct survival outcomes were identified. A nine-gene prognostic signature was established, effectively stratifying patients into high- and low-risk groups with significant survival differences. High-risk patients exhibited an immunosuppressive microenvironment, higher tumor mutational burden, and increased KRAS mutation frequency. Drug sensitivity analysis revealed subtype-specific therapeutic vulnerabilities. Single-cell and spatial transcriptomic analyses revealed that SEMA3 family genes modulate immune cell infiltration and spatial immune heterogeneity within the tumor microenvironment. Single-cell and spatial transcriptomics highlighted SEMA3C as a key mediator highly expressed in malignant and stromal cells, with spatially restricted patterns suggesting its role in modulating cell-cell communication and immune evasion.
conclusionThis study underscores the prognostic and immunological significance of SEMA3 family genes in PDAC. The developed risk model and nomogram demonstrate robust predictive ability, while SEMA3C emerges as a promising therapeutic target. Our findings provide insights into the heterogeneity of PDAC and support the development of personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.